This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Jeffrey Bockman
Executive VP and Oncology Practice Head at Cello Health BioConsulting


Jeff Bockman is EVP, Head of Oncology at Cello Health BioConsulting (Previously Defined Health). Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at DH. He often speaks at conferences on scientific and commercial issues in cancer, especially immuno-oncology. For example, Jeff recently chaired one of the main IO panels at BIO 2019. He was a Senior Research Scientist developing oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories in collaboration with Sidney Altman at Yale. Prior to this, Jeff was Assistant Research Professor at The George Washington University School of Medicine. He received a BA from University of California at San Diego, a PhD from the University of California at Berkeley on prions in collaboration with Stan Prusiner at UCSF, and an MA in Creative Writing from New York University. Jeff is a member of the Licensing Executives Society (LES), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Society of Gene and Cell Therapy (ASGCT), the Society for Immunotherapy of Cancer (SITC) and the New York Academy of Sciences (NYAS). Jeff has been part of the advisory board for ABL Bio, a Korean-based biologics platform company, and consults for the Swiss-based immunotherapy company ImmunOS.

Agenda Sessions

  • Oncology: The in-rush of funds for IO and non-IO

    On Demand